Table 1.
Baseline characteristics of patients of the Geneva cohort and comparison of NASH versus non-NASH and fibrotic versus non-fibrotic subjects.
| Variable | All subjects
|
NASH comparison
|
Fibrosis comparison
|
Statistical comparison
|
|||
|---|---|---|---|---|---|---|---|
| NASH | non-NASH | Fibrosis | Non-fibrosis | NASH vs non-NASH, p-value | Fibrosis vs non-fibrosis, p-value | ||
| N | 492 | 59 | 433 | 77 | 415 | ||
| Clinical | |||||||
| Male sex, n (%) | 89 (18) | 22 (13) | 67 (16) | 26 (34) | 63 (15) | 0.004 | 0.007 |
| Age (y) | 41 (34–49) | 46 (40–53) | 40 (33–48) | 43.6 (36–50) | 40.3 (33–49) | 0.004 | 1.0 |
| Age (>50y), n (%) | 104 (21) | 20 (34) | 84 (19) | 19 (25) | 85 (21) | 0.4 | 1.0 |
| Weight (kg) | 118 (108–132) | 123 (161–174) | 117 (110–130) | 125 (112–140) | 117 (108–131) | 0.4 | 0.2 |
| BMI (kg/m2) | 43.6 (41–47) | 44 (42–49) | 43 (41–47) | 44.4 (42–48) | 43.2 (41–47) | 1.0 | 1.0 |
| BMI (>45kg/m2), n (%) | 181 (37) | 25 (42) | 156 (36) | 30 (39) | 151 (36) | 1.0 | 1.0 |
| Diabetes, n (%) | 82 (17) | 27 (46) | 55 (13) | 27 (35) | 55 (13) | 0.002 | 0.002 |
| Arterial Hypertension, n (%) | 155 (32) | 30 (51) | 125 (29) | 31 (40) | 124 (30) | 0.03 | 1.0 |
| OSA, n (%) | 67 (13) | 12 (20) | 55 (13) | 12 (16) | 55 (13) | 1.0 | 1.0 |
| Ever smoked (n=297), n (%) | 136 (46) | 35 (66) | 101 (41) | 43 (62) | 93 (41) | 0.03 | 0.051 |
| Biological | |||||||
| Platelets (×109/L) | 268 (226–310) | 255 (200–300) | 274 (240–310) | 256 (220–310) | 272 (230–310) | 1.0 | 1.0 |
| Albumin (g/L) | 36 (35–39) | 38 (35–39) | 36 (35–38) | 38 (35–39) | 36 (35–38) | 1.0 | 1.0 |
| Ferritin (ng/mL) | 74 (35–142) | 147 (90–310) | 65.5 (32–120) | 137 (55–280) | 70 (31–122) | 0.002 | 0.002 |
| Bilirubin (mg/dL) | 0.59 (0.47–0.76) | 0.65 (0.5–0.8) | 0.60 (0.5–0.8) | 0.64 (0.5–0.8) | 0.60 (0.5–0.8) | 1.0 | 1.0 |
| AST (IU/L) | 20 (16–27) | 30 (25–42) | 19 (15–24) | 28 (21–42) | 19 (15–24) | 0.002 | 0.002 |
| ALT (IU/L) | 26 (17–42) | 47 (34–70) | 24 (17–36) | 44 (23–78) | 24 (17–36) | 0.002 | 0.002 |
| AlkPh (IU/L) | 71 (60–84) | 72 (60–94) | 71 (60–84) | 74 (62–91) | 70 (60–84) | 1.0 | 1.0 |
| GGT (IU/L) | 30 (20–48) | 52 (36–92) | 27.5 (19–43) | 48 (34–85) | 27 (19–43) | 0.002 | 0.002 |
| Total cholesterol (mg/dL) | 200 (170–230) | 200 (180–240) | 200 (170–220) | 210 (170–250) | 200 (170–220) | 1.0 | 0.5 |
| HDL cholesterol (mg/dL) | 140 (110–170) | 150 (120–190) | 130 (110–160) | 150 (130–190) | 130 (100–170) | 1.0 | 0.6 |
| Triglycerides (mg/dL) | 120 (90–190) | 160 (115–210) | 115 (80–180) | 160 (115–230) | 115 (80–180) | 0.004 | 0.002 |
| HOMA-IR | 5.4 (3.6–8.5) | 8 (5.3–17) | 5.1 (3.4–8.2) | 8.7 (5.4–16) | 5.1 (3.4–7.9) | 0.002 | 0.002 |
AlkPh, alkaline phosphatase; GGT, γ-glutamyltransferase; HOMA-IR, homeostatic model assessment-insulin resistance; OSA, obstructive sleep apnoea.
Continuous variables: median (IQR). P-values adjusted for multiple testing (Bonferroni correction).